Browse the corpus
Walk the Even Hospital Database by book and chapter — the raw source passages that ground Ask, DDx, and the rest.
1 passage
REFERENCES Chen RW, Gopal AK, Smith SE, et al, “Results From a Pivitol Phase II Study of Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL),” J Clin Oncol , 2011, 29(15s):8031 [abstract 8031 from 2011 ASCO Annual Meeting]. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf . Accessed January 21, 2013. Pro B, Avandi R, Brice P, et al, “Durable Remissions With Brentuximab Vedotin (SG-35): Updated Results of a Phase II Study in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma (sALCL),” J Clin Oncol , 2011, 29(15s):8032 [abstract 8032 from 2011 ASCO Annual Meeting]. Younes A, Bartlett NL, Leonard JP, et al, “Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas,” N Engl J Med, 2010, 363(19):1812-21. [PubMed 21047225 ] Younes A, Connors JM, Park SI, et al, “Frontline Therapy With Brentuximab Vedotin Combined With ABVD or AVD in Patients With Newly Diagnosed Advanced Stage Hodgkin Lymphoma,” Blood , 2011, 118(21):955 [abstract 955 from 2011 ASH Annual Meeting]. Topic 16806 Version 22.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.3 - C21.34 Licensed to: Morehouse School of Medicine | Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]